英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
nuz查看　nuz　在百度字典中的解释百度英翻中〔查看〕
nuz查看　nuz　在Google字典中的解释Google英翻中〔查看〕
nuz查看　nuz　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Oral therapy NUZ-001 cleared by FDA to join platform trial for ALS
    NUZ-001, an investigational oral therapy being developed by Neurizon Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS), is officially the ninth compound to be included in the HEALEY ALS platform trial
  • Neurizon Therapeutics
    NUZ-001 has completed a Phase 1 clinical study and subsequent 12-month open-label extension (OLE) in a small cohort of people living with ALS in Australia Across the study period, treatment appeared safe and generally well tolerated, with no treatment-related serious adverse events reported
  • FDA Lifts Clinical Hold on NUZ-001 - BioSpace
    Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease
  • NUZ-001 Preclinical Data Shows Multi-Pathway Protein Clearance Activity
    The data demonstrate that NUZ-001 and its sulfone metabolite increases activity of multiple protein clearance pathways in neuronal systems These findings provide additional insight into how NUZ-001 may assist neurons in managing the accumulation of aggregated proteins - a key feature of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS)
  • Neurizon Therapeutics (ASX:NUZ) Rises as New Data Strengthens Case for . . .
    Neurizon Therapeutics Ltd (ASX:NUZ) shares rose 4% to AUD 0 078 on 1 April 2026 after the company released new preclinical data for its lead drug candidate, NUZ-001
  • Neurizon unveils preclinical protein clearance data | Grafa
    Neurizon Therapeutics (ASX:NUZ) has unveiled compelling new preclinical data regarding its lead compound, NUZ-001, demonstrating an advancement in the fight against neurodegenerative diseases like Amyotrophic Lateral Sclerosis The findings characterise a unique biological mechanism of action
  • Neurizon Therapeutics (ASX: NUZ) NUZ-001 activates dual protein . . .
    Neurizon Therapeutics NUZ-001 activates two protein clearance pathways in ALS neurons Read what the preclinical data means ahead of the HEALEY trial
  • NUZ Stock Price Quote | Morningstar
    See the latest Neurizon Therapeutics Ltd stock price (NUZ:XASX), related news, valuation, dividends and more to help you make your investing decisions
  • Clearing the path for neurons as new data strengthens case for NUZ-001
    In laboratory models of human neurons, NUZ-001 appears to activate multiple internal systems that clear misfolded and aggregated proteins, a hallmark of conditions such as amyotrophic lateral sclerosis
  • Neurizon Therapeutics Reports Preclinical Findings for NUZ-001 in . . .
    Neurizon Therapeutics Limited (ASX: NUZ) has reported new preclinical findings for NUZ-001, its lead compound for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases The data demonstrates that NUZ-001 activates multiple protein clearance pathways, including aut- Kapitales Research, Australia





中文字典-英文字典  2005-2009